Literature DB >> 15054575

[Acute exacerbation of COPD].

C G Lange1, B Scheuerer, P Zabel.   

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) often develop into emergency situations that are associated with high morbidity and mortality. There is still a lack of a generally accepted definition for the risk stratification in AECOPD to guide an optimal diagnosis and treatment. In this article we propose a classification based on 4 degrees of severity, depending on whether outpatient treatment can be done by the patient himself or is provided by a physician and whether inpatient treatment is carried out on a general ward or on an intensive care unit. The pharmacological therapy of AECOPD relies on short acting bronchodilators, systemic corticosteroids and in case of purulent sputum on antibiotics. Longacting beta(2)-agonists or anticholinergics, theophyllin, mucolytic drugs or mechanical percussion to the chest by a physiotherapist have no proven value in the emergency treatment of AECOPD. In respiratory failure the use of oxygen therapy and non-invasive positive pressure ventilation (NIPPV) can often prevent the need for endotracheal intubation and controlled mechanical ventilation, thus preventing associated risks like the development of nosocomial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054575     DOI: 10.1007/s00108-004-1170-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

Review 1.  [Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für pneumologie].

Authors:  H Worth; R Buhl; U Cegla; C P Criée; A Gillissen; P Kardos; D Köhler; H Magnussen; R Meister; D Nowak; W Petro; K F Rabe; G Schultze-Werninghaus; H Sitter; H Teschler; T Welte; R Wettengel
Journal:  Pneumologie       Date:  2002-11

2.  Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine.

Authors:  S Jonsson; G Vidarsson; H Valdimarsson; G Schiffman; R Schneerson; I Jonsdottir
Journal:  Eur Respir J       Date:  2002-10       Impact factor: 16.671

3.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 6.  Toward a consensus definition for COPD exacerbations.

Authors:  R Rodriguez-Roisin
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

7.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Authors:  E Monsó; J Ruiz; A Rosell; J Manterola; J Fiz; J Morera; V Ausina
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

8.  Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure.

Authors:  N Kramer; T J Meyer; J Meharg; R D Cece; N S Hill
Journal:  Am J Respir Crit Care Med       Date:  1995-06       Impact factor: 21.405

Review 9.  Inpatient management of chronic obstructive pulmonary disease.

Authors:  J K Stoller; P A Lange
Journal:  Respir Care Clin N Am       Date:  1998-09

Review 10.  Chronic obstructive pulmonary disease.

Authors:  P M A Calverley; Paul Walker
Journal:  Lancet       Date:  2003-09-27       Impact factor: 79.321

View more
  1 in total

Review 1.  [Bronchial asthma and chronic obstructive pulmonary disease with acute exacerbation: preclinical differential diagnostic and emergency treatment].

Authors:  B Friege; L Friege; J Pelz; M Weber; T von Spiegel; S Schröder
Journal:  Anaesthesist       Date:  2009-06       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.